3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
This study aims to evaluate the safety and efficacy of 3D1002 alone or in combination with oxycodone hydrochloride sustained-release tablets (OxyContin) for the management of moderate or severe cancer pain.
Epistemonikos ID: 575945181888de846162642c049a678c29f6b130
First added on: May 10, 2024